We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Organoids Aid Discovery of New Approaches for Treating Pancreatic Cancer

By LabMedica International staff writers
Posted on 25 Jan 2015
Cancer researchers have established a method for culturing organoids from normal and cancerous mouse and human pancreatic tissues that is expected to boost development of personalized treatment approaches for this deadly disease.

Since pancreatic cancer is one of the most lethal malignancies due to its late diagnosis and limited response to treatment, methods to identify and study molecular pathways involved in tumor development are urgently needed. More...
Towards this end investigators at Cold Spring Harbor Laboratory (NY, USA) established organoid models from normal and cancerous mouse and human pancreas tissues. Pancreatic organoids could be rapidly generated from resected tumors and biopsies, survive cryopreservation, and exhibit ductal- and disease-stage-specific characteristics. Normal ductal cells that are able to develop into pancreatic cancer represent only about 10% of the cells in the pancreas, but the organoids were entirely composed of ductal cells, which eliminated surrounding cell types that often contaminate pancreatic samples.

Details published in the December 2014 online edition of the journal Cell revealed that the organoids were grown as hollow spheres within a complex gel-like substance filled with growth-inducing factors and connecting fibers. Once they had grown to a sufficient size, the organoids were transplanted into mice, where they fully recapitulated all the stages of pancreatic cancer development from early-grade neoplasms that progressed to locally invasive and metastatic carcinomas.

Due to their ability to be manipulated genetically, organoids served as an ideal platform to probe genetic cooperation. Comprehensive transcriptional and proteomic analyses of mouse pancreatic organoids revealed genes and pathways altered during disease progression. The confirmation of many of these protein changes in human tissues demonstrated that organoids were a useful model system to discover characteristics of this deadly malignancy.

“With this development, we are now able to culture both mouse and human organoids, providing a very powerful tool in our fight against pancreatic cancer,” said senior author Dr. David Tuveson, professor of pancreatic cancer medicine at Cold Spring Harbor Laboratory. “We hope to make this available to the entire pancreatic cancer research community.”

Related Links:

Cold Spring Harbor Laboratory



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.